Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07283718Active Not Recruiting

The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis

Role: lead

NCT07180056Recruiting

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Role: lead

NCT07180082Phase 2Recruiting

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

Role: lead

NCT07180160Phase 2Recruiting

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Role: lead

NCT07180264Recruiting

Trastuzumab Deruxtecan in Advanced Breast Cancer

Role: lead

NCT05876065Not ApplicableRecruiting

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Role: lead

All 6 trials loaded